VIVS — VivoSim Labs, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1497253 ·
Last close
$1.29
Market Cap
$3.73M
52W High
$2.23
52W Low
$1.22
ADV30
49,035
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 26,000 | 26,000 | -2,750,000 | -2,691,000 | 6,960,000 | 4,288,000 | 2,519,000 |
| Sep 2025 | 28,000 | 28,000 | -2,635,000 | -2,545,000 | 9,686,000 | 6,677,000 | 2,621,000 |
| Jun 2025 | 37,000 | 37,000 | -2,915,000 | -2,843,000 | 11,978,000 | 9,055,000 | 2,440,000 |
| Mar 2025 | 51,000 | 51,000 | -3,154,000 | 6,852,000 | 14,650,000 | 11,312,000 | 4,158,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,624,000
Investing CF
$9,001,000
Financing CF
$4,750,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.43
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-350,236,000
Inventory
$0
Receivables
$1,044,000
ST Investments
—
EBIT TTM
$-1,212,000
Pretax Income TTM
$-1,225,000
Interest Exp TTM
$13,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$142,000
EBITDA
$-11,221,000
Free Cash Flow
$-7,895,875
Enterprise Value
$70,828
Total Cash
$4,288,000
Total Debt
$812,000
Shares Out
2,894,519
Trailing EPS
$1.76
Book Value
$1.70
ROE
-51.1%
ROA
-132.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 144,000 | -12,616,000 | -2,488,000 | 14,650,000 | 4,158,000 | — | -9,461,000 |
| Mar 2024 | 109,000 | -15,086,000 | -14,671,000 | 6,349,000 | 2,748,000 | — | -14,653,000 |
| Mar 2023 | 370,000 | -17,731,000 | -17,259,000 | 20,313,000 | 4,984,000 | — | -12,408,000 |
| Mar 2022 | 1,500,000 | -11,479,000 | -11,448,000 | 33,296,000 | 3,087,000 | — | -8,453,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | $3.42M | $0.18 | — |
| AIM | AIM ImmunoTech Inc. | $3.39M | $0.23 | — |
| APTOF | Aptose Biosciences Inc. | $4.29M | $1.68 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $5.03M | $0.69 | — |
| BCAB | BioAtla, Inc. | $6.48M | $3.91 | — |
News headlines (Yahoo Finance, 1h cache)
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
2026-04-28 12:05 · Yahoo
VivoSim Announces Pricing of up to a $4 Million Public Offering
2026-04-01 12:05 · Yahoo
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
2026-03-24 12:05 · Yahoo
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
2026-03-03 13:05 · Yahoo
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
2026-02-11 13:05 · Yahoo
NIO Inc. Announces Profit Alert for the Fourth Quarter of 2025
2026-02-05 10:00 · Yahoo
NIO January Deliveries Nearly Double Year On Year
2026-02-02 11:59 · Yahoo
NIO Inc. Provides January 2026 Delivery Update
2026-02-01 08:00 · Yahoo
Top Midday Gainers
2026-01-30 18:48 · Yahoo
BC-Most Active Stocks
2026-01-30 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.